Search Results - "Bott‐Kitslaar, Dalene M."

Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer‐associated venous thromboembolism by Wysokinski, Waldemar E., Houghton, Damon E., Casanegra, Ana I., Vlazny, Danielle T., Bott‐Kitslaar, Dalene M., Froehling, David A., Hodge, David O., Peterson, Lisa G., Mcbane, Robert D.

“…To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer‐associated venous thromboembolism (Ca‐VTE), consecutive patients…”
Get full text

Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight by Wysokinski, Waldemar E., Froehling, David A., Houghton, Damon E., McBane, Robert D., Vlazny, Danielle T., Bott‐Kitslaar, Dalene M., Kuczmik, Wiktoria, Sutkowska, Karolina, Bator, Kaja, Hodge, David O., Peterson, Lisa G., Casanegra, Ana I.

“…Objectives To investigate the association of extremes in bodyweight (EBW) and outcomes in patients with acute venous thromboembolism (VTE). Recurrent VTE,…”
Get full text

Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location by Janczak, Dawid T., Mimier, Malgorzata K., McBane, Robert D., Kamath, Patrick S., Simmons, Benjamin S., Bott-Kitslaar, Dalene M., Lenz, Charles J., Vargas, Emily R., Hodge, David O., Wysokinski, Waldemar E.

“…To assess the outcome of direct oral anticoagulants (DOACs), specifically Xa inhibitors: rivaroxaban and apixaban, for the treatment of venous thromboembolism…”
Get full text

Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-center Registry by Bott-Kitslaar, Dalene M., APRN, CNP, Saadiq, Rayya A., DO, McBane, Robert D., MD, Loprinzi, Charles L., MD, Ashrani, Aneel A., MD, Ransone, Teresa R., PA-C, Wolfgram, Alissa A., RN, Berentsen, Michelle M., RN, Wysokinski, Waldemar E., MD

“…Abstract Objective The purpose of this study is to evaluate the efficacy and safety of rivaroxaban in patients with venous thromboembolism and active…”
Get full text

Adverse Events and Mortality in Anticoagulated Patients with Different Categories of Pulmonary Embolism by Cambron, Julia C., Saba, Elias S., McBane, Robert D., Casanegra, Ana I., Villarraga, Hector R., Houghton, Damon E., Vlazny, Danielle T., Froehling, David, Hodge, David, Peterson, Lisa G., Bott-Kitslaar, Dalene M., Wysokinski, Waldemar E.

“…To determine whether the pulmonary embolism (PE) categories of massive, submassive, PE with no right ventricle dysfunction (NRVD), and subsegmental only (SSO)…”
Get full text

Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism by Bott-Kitslaar, Dalene M., McBane, Robert D., Casanegra, Ana I., Houghton, Damon E., Froehling, David A., Vlazny, Danielle T., Ashrani, Aneel A., Hodge, David O., Vargas, Emily R., Bartlett, Matthew A., Saadiq, Rayya A., Daniels, Paul R., Shields, Raymond C., Lenz, Charles J., Lang, Teresa R., Wysokinski, Waldemar E.

“…To compare the clinical efficacy and safety of apixaban with those of rivaroxaban for the treatment of acute venous thromboembolism (VTE). Consecutive patients…”
Get full text

Safety and Efficacy of Apixaban and Rivaroxaban for the Treatment of Upper Extremity Deep Vein Thrombosis by Houghton, Damon E., Bott-Kitslaar, Dalene M., Vargas, Emily, Hodge, David O., Ransone, Teresa R., Casanegra, Ana, Peterson, Lisa, McBane, Robert D., Wysokinski, Waldemar E.

“…Background: Patients with upper extremity deep vein thrombosis (UE-DVT) have unique risk factors determining their incidence and recurrence, and were not…”
Get full text

Cancer-Associated Thrombosis and Bleeding Risk in Gastrointestinal Malignancies with Apixaban and Rivaroxaban Compared to Low Molecular Weight Heparin by Houghton, Damon E., Bott-Kitslaar, Dalene M., Vargas, Emily, Hodge, David O., Lang, Teresa R, Peterson, Lisa, Casanegra, Ana I, McBane, Robert D., Wysokinski, Waldemar E., Froehling, David A

“…Background: Randomized control trials (RCT) have examined the safety and efficacy of direct oral anticoagulants (DOACs) compared to dalteparin in patients with…”
Get full text